| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ikaros Transcription Factor | 19 | 2021 | 26 | 2.610 |
Why?
|
| B-Lymphocytes | 5 | 2021 | 329 | 1.570 |
Why?
|
| Lymphopoiesis | 6 | 2016 | 16 | 1.540 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2021 | 70 | 1.420 |
Why?
|
| Myeloid Cells | 4 | 2015 | 57 | 1.110 |
Why?
|
| Heterografts | 2 | 2017 | 70 | 1.090 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2021 | 61 | 1.040 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2015 | 268 | 0.940 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 11 | 0.930 |
Why?
|
| Casein Kinase II | 9 | 2021 | 11 | 0.910 |
Why?
|
| Receptors, Cytokine | 4 | 2021 | 19 | 0.900 |
Why?
|
| Interleukin-7 | 2 | 2016 | 18 | 0.880 |
Why?
|
| Leukemia | 4 | 2017 | 117 | 0.880 |
Why?
|
| Cytokines | 4 | 2020 | 866 | 0.880 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2021 | 29 | 0.810 |
Why?
|
| Fetal Blood | 7 | 2018 | 131 | 0.780 |
Why?
|
| STAT5 Transcription Factor | 2 | 2017 | 18 | 0.720 |
Why?
|
| Precursor Cells, B-Lymphoid | 2 | 2016 | 3 | 0.670 |
Why?
|
| Signal Transduction | 12 | 2021 | 2689 | 0.640 |
Why?
|
| Stromal Cells | 2 | 2017 | 113 | 0.640 |
Why?
|
| Leukemia, T-Cell | 3 | 2014 | 21 | 0.570 |
Why?
|
| Mice | 22 | 2020 | 8474 | 0.560 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 94 | 0.550 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 9 | 0.550 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 304 | 0.530 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 245 | 0.520 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2015 | 4 | 0.510 |
Why?
|
| Animals | 29 | 2020 | 20881 | 0.500 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.490 |
Why?
|
| Cell Lineage | 6 | 2015 | 146 | 0.480 |
Why?
|
| CD24 Antigen | 1 | 2014 | 6 | 0.470 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 17 | 0.470 |
Why?
|
| Receptors, Complement 3d | 1 | 2014 | 45 | 0.460 |
Why?
|
| Cytosol | 1 | 2013 | 123 | 0.450 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 157 | 0.450 |
Why?
|
| Cervical Ripening | 1 | 2012 | 2 | 0.430 |
Why?
|
| Parturition | 1 | 2012 | 15 | 0.430 |
Why?
|
| Cervix Uteri | 1 | 2012 | 64 | 0.420 |
Why?
|
| Macrophage Activation | 1 | 2012 | 75 | 0.420 |
Why?
|
| Phosphoproteins | 1 | 2013 | 202 | 0.410 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 230 | 0.410 |
Why?
|
| Humans | 50 | 2021 | 68618 | 0.400 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 215 | 0.400 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1174 | 0.390 |
Why?
|
| Cell Differentiation | 12 | 2019 | 1034 | 0.390 |
Why?
|
| Neutrophils | 2 | 2021 | 204 | 0.330 |
Why?
|
| Cell Line | 8 | 2021 | 1752 | 0.310 |
Why?
|
| Transcription Factors | 4 | 2013 | 753 | 0.300 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2021 | 118 | 0.300 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 163 | 0.300 |
Why?
|
| bcl-X Protein | 2 | 2020 | 36 | 0.290 |
Why?
|
| Dendritic Cells | 3 | 2017 | 201 | 0.290 |
Why?
|
| Cells, Cultured | 11 | 2017 | 2673 | 0.290 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2013 | 86 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.270 |
Why?
|
| Interleukin-1beta | 2 | 2017 | 88 | 0.260 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2017 | 114 | 0.260 |
Why?
|
| Bone Marrow | 2 | 2020 | 168 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2016 | 498 | 0.240 |
Why?
|
| Palmitic Acid | 2 | 2017 | 51 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 307 | 0.230 |
Why?
|
| Repressor Proteins | 2 | 2015 | 183 | 0.230 |
Why?
|
| Blood Cells | 2 | 2013 | 27 | 0.220 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 1033 | 0.220 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1070 | 0.220 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2013 | 11 | 0.210 |
Why?
|
| Genetic Vectors | 4 | 2017 | 312 | 0.210 |
Why?
|
| Gene Deletion | 2 | 2021 | 235 | 0.210 |
Why?
|
| Protein Phosphatase 1 | 2 | 2014 | 36 | 0.200 |
Why?
|
| Extracellular Traps | 1 | 2021 | 9 | 0.190 |
Why?
|
| Blood Platelets | 2 | 2021 | 284 | 0.190 |
Why?
|
| Cholera Toxin | 2 | 2011 | 30 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 710 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 74 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 72 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2017 | 223 | 0.180 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2020 | 3 | 0.180 |
Why?
|
| Antigens, CD34 | 4 | 2013 | 75 | 0.180 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2017 | 64 | 0.170 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 132 | 0.170 |
Why?
|
| Models, Biological | 3 | 2016 | 981 | 0.170 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 81 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 84 | 0.170 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 142 | 0.170 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 63 | 0.160 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2018 | 1 | 0.160 |
Why?
|
| Centromere | 2 | 2009 | 15 | 0.160 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 562 | 0.160 |
Why?
|
| Medication Reconciliation | 1 | 2018 | 18 | 0.160 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 11 | 0.160 |
Why?
|
| Transcriptome | 1 | 2020 | 164 | 0.160 |
Why?
|
| Leptin | 1 | 2018 | 80 | 0.150 |
Why?
|
| Thymocytes | 2 | 2014 | 11 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2021 | 326 | 0.150 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 89 | 0.150 |
Why?
|
| Phosphorylation | 7 | 2017 | 1200 | 0.140 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 4 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2020 | 324 | 0.140 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 19 | 0.140 |
Why?
|
| Infant, Premature | 1 | 2018 | 284 | 0.140 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 226 | 0.140 |
Why?
|
| Coronary Artery Bypass | 3 | 2007 | 218 | 0.130 |
Why?
|
| Gene Expression | 2 | 2016 | 770 | 0.130 |
Why?
|
| Gestational Age | 2 | 2018 | 389 | 0.130 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 6 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2018 | 294 | 0.130 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 17 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 53 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 116 | 0.130 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2015 | 1 | 0.130 |
Why?
|
| Histone Deacetylase 1 | 1 | 2015 | 32 | 0.130 |
Why?
|
| Transgenes | 1 | 2015 | 92 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 122 | 0.130 |
Why?
|
| Flow Cytometry | 3 | 2018 | 489 | 0.130 |
Why?
|
| Point Mutation | 2 | 2013 | 97 | 0.130 |
Why?
|
| Immunologic Factors | 2 | 2017 | 87 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1293 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2016 | 124 | 0.120 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2014 | 5 | 0.120 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2007 | 250 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 282 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 124 | 0.120 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2014 | 21 | 0.120 |
Why?
|
| Human papillomavirus 16 | 1 | 2014 | 23 | 0.120 |
Why?
|
| Monocytes | 1 | 2015 | 210 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 271 | 0.120 |
Why?
|
| Female | 11 | 2021 | 38074 | 0.110 |
Why?
|
| Species Specificity | 1 | 2014 | 303 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 331 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 455 | 0.110 |
Why?
|
| Coculture Techniques | 2 | 2013 | 147 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 190 | 0.110 |
Why?
|
| Prognosis | 4 | 2021 | 2093 | 0.110 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 134 | 0.110 |
Why?
|
| Enzyme Induction | 1 | 2012 | 119 | 0.110 |
Why?
|
| Proteins | 1 | 2016 | 474 | 0.110 |
Why?
|
| Vitamin D | 1 | 2017 | 516 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 189 | 0.100 |
Why?
|
| Middle Aged | 7 | 2018 | 21147 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2455 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 711 | 0.100 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 626 | 0.100 |
Why?
|
| DNA-Binding Proteins | 3 | 2006 | 700 | 0.100 |
Why?
|
| Leukemia, B-Cell | 1 | 2011 | 7 | 0.100 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 20 | 0.100 |
Why?
|
| S Phase | 1 | 2011 | 38 | 0.100 |
Why?
|
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2011 | 1 | 0.100 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide, Type II | 1 | 2011 | 1 | 0.100 |
Why?
|
| Glutamate Decarboxylase | 1 | 2011 | 18 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1664 | 0.100 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 217 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 1851 | 0.100 |
Why?
|
| Male | 9 | 2021 | 37321 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 194 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 1076 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 223 | 0.090 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2011 | 23 | 0.090 |
Why?
|
| Proinsulin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2011 | 114 | 0.090 |
Why?
|
| Schwann Cells | 1 | 2010 | 33 | 0.090 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 33 | 0.090 |
Why?
|
| Protein Isoforms | 3 | 2011 | 246 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 90 | 0.090 |
Why?
|
| Mice, Inbred NOD | 3 | 2015 | 138 | 0.090 |
Why?
|
| Autoantigens | 1 | 2010 | 91 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 597 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1851 | 0.080 |
Why?
|
| Adult | 5 | 2016 | 21403 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 493 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 376 | 0.080 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2010 | 158 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 647 | 0.080 |
Why?
|
| Lentivirus | 3 | 2013 | 35 | 0.080 |
Why?
|
| Heterochromatin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2550 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2010 | 682 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2009 | 305 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 507 | 0.070 |
Why?
|
| Granulocytes | 1 | 2007 | 22 | 0.070 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2007 | 48 | 0.070 |
Why?
|
| Cyclins | 1 | 2007 | 50 | 0.070 |
Why?
|
| Isoxazoles | 1 | 2007 | 22 | 0.070 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2007 | 22 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2016 | 615 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 60 | 0.070 |
Why?
|
| Thiophenes | 1 | 2007 | 76 | 0.070 |
Why?
|
| Pregnancy | 1 | 2012 | 2334 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 2791 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 514 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 82 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 852 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 508 | 0.060 |
Why?
|
| Cell Separation | 2 | 2020 | 132 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 209 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2007 | 597 | 0.060 |
Why?
|
| Endothelin-1 | 1 | 2005 | 122 | 0.060 |
Why?
|
| Endothelins | 1 | 2004 | 57 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2007 | 1451 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2017 | 230 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 499 | 0.050 |
Why?
|
| Cellular Reprogramming | 2 | 2013 | 22 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 30 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2005 | 358 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 411 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 652 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1692 | 0.050 |
Why?
|
| Platelet Activation | 1 | 2021 | 24 | 0.050 |
Why?
|
| Phenazines | 1 | 2021 | 2 | 0.050 |
Why?
|
| Binding Sites | 2 | 2017 | 631 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2021 | 20 | 0.050 |
Why?
|
| Porphyromonas gingivalis | 1 | 2021 | 33 | 0.050 |
Why?
|
| Protein Binding | 3 | 2009 | 1027 | 0.050 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 5 | 0.050 |
Why?
|
| PAX5 Transcription Factor | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2020 | 37 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 82 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 326 | 0.040 |
Why?
|
| Child | 2 | 2021 | 6405 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 146 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 43 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 231 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1745 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 168 | 0.040 |
Why?
|
| Receptors, Leptin | 1 | 2018 | 6 | 0.040 |
Why?
|
| P-Selectin | 1 | 2018 | 16 | 0.040 |
Why?
|
| Myocardium | 1 | 2005 | 1204 | 0.040 |
Why?
|
| Adenosine Diphosphate | 1 | 2018 | 66 | 0.040 |
Why?
|
| Ohio | 1 | 2018 | 64 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2017 | 7029 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 320 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2017 | 10 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 2017 | 23 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 85 | 0.040 |
Why?
|
| Urban Population | 1 | 2018 | 255 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2017 | 34 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 78 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2017 | 237 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1603 | 0.030 |
Why?
|
| Thymus Gland | 2 | 2008 | 97 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 137 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 108 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 483 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2016 | 89 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1615 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 61 | 0.030 |
Why?
|
| DNA | 2 | 2009 | 597 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 34 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 29 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 349 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2007 | 238 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 52 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 714 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 3705 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 742 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 216 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 214 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 432 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2015 | 100 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 335 | 0.030 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 370 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 434 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3259 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 468 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 25 | 0.030 |
Why?
|
| Teratoma | 1 | 2013 | 22 | 0.030 |
Why?
|
| Pulmonary Artery | 2 | 2007 | 323 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 20 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2013 | 17 | 0.030 |
Why?
|
| Karyotyping | 1 | 2013 | 74 | 0.030 |
Why?
|
| Connective Tissue | 1 | 2013 | 61 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2013 | 41 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 159 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 848 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 238 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 978 | 0.030 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2013 | 63 | 0.030 |
Why?
|
| Plasmids | 1 | 2013 | 258 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2013 | 145 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 659 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 756 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2011 | 25 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 16 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 95 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2011 | 90 | 0.020 |
Why?
|
| Gene Order | 1 | 2010 | 13 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 34 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 194 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2010 | 144 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 329 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2009 | 77 | 0.020 |
Why?
|
| Protein Stability | 1 | 2009 | 90 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7367 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1641 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2009 | 74 | 0.020 |
Why?
|
| Cyclin H | 1 | 2007 | 1 | 0.020 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2007 | 9 | 0.020 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2007 | 10 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2007 | 10 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2007 | 18 | 0.020 |
Why?
|
| G1 Phase | 1 | 2007 | 42 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 235 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 139 | 0.020 |
Why?
|
| Amino Acids | 1 | 2008 | 131 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 50 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2007 | 21 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 75 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 97 | 0.020 |
Why?
|
| Tretinoin | 1 | 2007 | 92 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 179 | 0.020 |
Why?
|
| Time Factors | 2 | 2005 | 4655 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.020 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 328 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1447 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2005 | 110 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 284 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5717 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2005 | 58 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 397 | 0.020 |
Why?
|
| Microdialysis | 1 | 2005 | 147 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2006 | 546 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2004 | 24 | 0.010 |
Why?
|
| Electrolytes | 1 | 2004 | 47 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 447 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 248 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 383 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 277 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 780 | 0.010 |
Why?
|